Evidence-based recommendations on eptinezumab (VYEPTI) for preventing migraine in adults. Commercial arrangement There is a simple discount patient access scheme for eptinezumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact United...

Texte intégral